Hot Stocks to Watch: KLA-Tencor Corporation (NASDAQ:KLAC), Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

KLA-Tencor Corporation (NASDAQ:KLAC)

The shares of KLA-Tencor Corporation (NASDAQ:KLAC) started off the last trading session with the price of $116.09 while closing the day with the price of $112.92. The shares of KLA-Tencor Corporation (NASDAQ:KLAC) Fell -4.35% with the Loss of -3.17 points.

The shares of KLA-Tencor Corporation (NASDAQ:KLAC) traded with the day volume of 1.62 Million shares whereas its average trading volume is 1.49 Million.

While analyzing the past performance of the stock we can see that the shares of KLA-Tencor Corporation (NASDAQ:KLAC) Loss -6.53% in the last week while rising 2.96% in the last month. Past quarter performance shows the green light with 1.16%. The semi-annual and annual performance shows 13.31% and 18.15% respectively.

Some critical values of the shares of KLA-Tencor Corporation (NASDAQ:KLAC) to be discussed here are: the beta which shows the value at 1.49 while Average True Range of KLA-Tencor Corporation (NASDAQ:KLAC) demonstrate the value at 3.64. The weekly and monthly volatility of the shares of KLA-Tencor Corporation (NASDAQ:KLAC) are indicated at 3.56% and 2.83%. Also to discuss here is the Relative Strength Index or RSI which is depicted at 43.69.

While studying the financial position of the shares of KLA-Tencor Corporation (NASDAQ:KLAC), we can see that the Market capitalization of the company is at 17.71 Billion. The shares outstanding for the company is 156.87 Million and the shares float stands at 156.28 Million. The income of the company stand at 1.1 Billion while the sales stand at 3.8 Billion.

Here are some critical ratios for a financial perspective: Earnings Per Share or EPS of the company stand at 6.97, Price to Earnings or P/E is at 16.19, Price to Sales P/S show the value of 4.66, the Return on Asset ROA stood at 0.12 and the Return on Equity ROE depicted at 0.508 while Return on Investment ROI is at 0.242.


Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) started its previous trading session at $32.8 and closed at $31.7 showing a Fell of -4.89 Percent.

The Company traded with an average Volume of 1.31 Million whereas, its Day Volume stood at 1.62 Million.

Looking at the performance of the stock, Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Loss -12.21% in the last week in its shares price and -29.41% in the last month. Quarterly performance shows a red of -37.83 Percent while Semi-Annual and Annual performances shows a -39.81 and -17.68 percent respectively.

Beta for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) stands at 1.33 while the ATR (average true range) is at 2.37. The Stock’s Weekly and Monthly Volatility is 4.80% and 6.15% respectively showing a RSI value of 30.05.

While studying the financial position of the shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), we can see that the Market capitalization of the company is at 2.15 Billion. The shares outstanding for the company is 67.8 Million and the shares float stands at 65 Million.

The Company generated an income of -286100000 and the sales of 22.5 Million in the Trailing Twelve Months period.

While analyzing the stock from technical aspects, Diluted Earnings per share stands at $-4.77 a share. P/E (price to earnings) and P/S (price to sales) values are 0 and 95.52 respectively.

The Return on Assets stands at -0.619, ROE shows a value of -1.095 and ROI for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) is -0.604 as of Trailing Twelve Months period.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

View all contributions by

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Comment